Basal cell carcinoma of the scrotum

Hernandez-Aragues, Ignacio; Baniandrés‐Rodríguez, Ofelia

doi:10.1016/j.acuroe.2016.08.008

Cited by 5 publications

(6 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…BCC on the scrotum has been reported to be more aggressive with a higher risk of metastasis than that located in other areas, 3 possibly due to the lack of subcutaneous tissue in the thin scrotal skin and to hypervascularization. Reported risk factors for BCC on the scrotum are a history of radiotherapy, chronic dermatitis, and immunocompromise 3 . However, the present case had none of these factors.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Giant basal cell carcinoma of the scrotum: A case report and review of the literature

Ogawa

Kitamura

Seo

et al. 2022

JEADV Clinical Practice

View full text Add to dashboard Cite

Basal cell carcinoma (BCC) is the most common skin cancer. However, BCC on the scrotum is very rare, with an incidence of 0.03%. Giant BCC, in which the tumour is larger than 5 cm, has also been reported as a rare variant. Here, we report a 71‐year‐old male with a giant BCC on the scrotum and review similar cases reported in English. None of the four cases of giant BCC on the scrotum, including the present case, showed lymph node or distant metastasis. Wide local excision was conducted in all cases, and no recurrence was reported. The role of human papilloma virus in scrotal BCC development remains unclear.

show abstract

Section: Discussionmentioning

confidence: 99%

“…2 Giant BCC, in which the tumour exceeds 5 cm at the widest point, is also a rare variant of BCC. 3 We report a case of giant BCC on the scrotum and review the reported cases.…”

Section: Introductionmentioning

confidence: 99%

Giant basal cell carcinoma of the scrotum: A case report and review of the literature

Ogawa

Kitamura

Seo

et al. 2022

JEADV Clinical Practice

View full text Add to dashboard Cite

show abstract

“…Men with suspected clinical prostate cancer (PCa) based on abnormal digital rectal examination (DRE) or increased prostate specific antigen (PSA) level are conventionally recommended to undergo transrectal ultrasonography-guided biopsy of the prostate (TRUS-Bx) (1). However, TRUS-Bx has a false negative rate of 10-20% especially with lesions in transition zone, anterior and apex of the prostate (2).…”

Section: Introductionmentioning

confidence: 99%

Single center results of magnetic resonance imaging ultrasound guided fusion prostate biopsy obtained patients

Yılmaz

Aybal²,

Özdemi̇r³

et al. 2021

New J Urol

View full text Add to dashboard Cite

Objective: We aimed to evaluate magnetic resonance imaging-ultrasound guided fusion prostate biopsy (MRI- US FPBx) results from a single center and to compare with current literature. Material and Methods: Between January 2016 and July 2019, MRI-US FPBx pathological and imaging results of 358 men were retrospectively analyzed. PI-RADS scores were determined as 3, 4 and 5 in 222 (62%), 107 (29.8%) and 29 (8.1%) patients, respectively. Totally 454 lesions were underwent MRI-US FPBx. 303 (66.7%) lesions were scored as PI-RADS 3, 120 (26.4%) lesions were scored as PI-RADS 4 and 31 (6.8%) lesions were scored as PI-RADS 5. 315 (69.3%) of lesions were in peripheral zone, 26 (5.7%) were in central zone, 111 (24.4%) were in transitional zone and 2 of them were in anterior fibromuscular stroma. Results: Overall prostate cancer detection rate was 36.3%. Concerning detection rates, MRI-US FPBx alone and transrectal ultrasonography guided prostate biopsy (TRUS-Bx) alone were 27.6% and 26.5%, respectively. Cancer detection rate only through MRI-US FPBx PIRADS-3 and PI-RADS 4&5 were 6.9% and 20.6%, respectively. Clinically significant prostate cancer (csPCa) rates were evaluated and csPCa to overall prostate cancer (PCa) rates for TRUS-Bx, MRI-US FPBx and combined techniques were 16.8%, 35.4% and 39.2%, respectively. Results of 11 patients were evaluated as benign. Conclusion: MRI-US FPBx significantly increases success rate of prostate biopsy procedure. Regarding current MRI technology, it is not appropriate to consider MRI-US FPBx as a stand-alone biopsy option without concomitant with TRUS-Bx. Keywords: prostate cancer; biopsy; MRI; fusion

show abstract

“…The pathogenesis remains unknown: while UV light, chemical agents like soot, coal tar, pitch, different types of lubricant oils or creosotes and radiotherapy are known to support the development of BCC, patients reported with scrotal BCC do not show exposure to these carcinogens. [4][5][6][7][8] It has been proposed that genital papillomavirus (HPV) infection might promote the growth of scrotal BCCs; however, a large study failed to detect HPV in skin biopsies from scrotal BCCs. 9 Since the median age of patients with scrotal BCC amounts to 66-70 years, reduced immunosurveillance due to increased age has been suspected as a potential risk factor.…”

mentioning

confidence: 99%